Biapigenin, Candidate of an Agonist of Human Peroxisome Proliferator-Activated Receptor γ with Anticancer Activity

被引：3

作者：

Kim, Jin-Kyoung ^{[1
]}

Shin, Soyoung ^{[1
]}

Lee, Jee-Young ^{[1
]}

Lee, Sojung ^{[1
]}

Lee, Eunjung ^{[1
]}

Jin, Qinglong ^{[2
]}

Lee, Juneyoung ^{[3
]}

Woo, Eun-Rhan ^{[2
]}

Lee, Dong Gun ^{[3
]}

Yoon, Do-Young ^{[1
]}

Kim, Yangmee ^{[1
]}

机构：

[1] Konkuk Univ, Dept Biosci & Biotechnol, Bio Mol Informat Ctr, Seoul 143701, South Korea

[2] Chosun Univ, Coll Pharm, Kwangju 501759, South Korea

[3] Kyungpook Natl Univ, Coll Nat Sci, Sch Life Sci & Biotechnol, Taegu 702701, South Korea

来源：

BULLETIN OF THE KOREAN CHEMICAL SOCIETY | 2011年 / 32卷 / 08期

基金：

新加坡国家研究基金会;

关键词：

Biapigenin; PPAR gamma agonist; Biflavonoid; Anticancer agents; PPAR-GAMMA; NUCLEAR RECEPTORS; ALPHA; BIFLAVONOIDS; FLAVONOIDS; INDOMETHACIN; LIGANDS; DISEASE; TARGETS; BIOLOGY;

D O I：

10.5012/bkcs.2011.32.8.2717

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Peroxisome proliferator-activated receptors (PPARs) are a subfamily of nuclear receptors (NRs). Human peroxisome proliferator-activated receptor gamma (hPPAR gamma) has been implicated in the pathology of numerous diseases, including obesity, diabetes, and cancer. ELISA-based hPPAR gamma activation assay showed that biapigenin increased the binding between hPPAR gamma and steroid receptor coactivator-1 (SRC-1) by approximately 3-fold. In order to confirm that biapigenin binds to hPPAR gamma, fluorescence quenching experiment was performed. The results showed that biapigenin has higher binding affinity to hPPAR gamma at nanomolar concentrations compared to indomethacin. Biapigenin showed anticancer activity against HeLa cells. Biapigenin was noncytotoxic against HaCa T cell. All these data implied that biapigenin may be a potent agonist of hPPAR gamma with anticancer activity. We will further investigate its anticancer effects against human cervical cancer.

引用

页码：2717 / 2721

页数：5

共 32 条

[21]

McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892

[22]

Narayana K. Raj, 2001, Indian Journal of Pharmacology, V33, P2

[23] Amphipathic α-helical peptide, HP (2-20), and its analogues derived from Helicobacter pylori:: Pore formation mechanism in various lipid compositions [J].

Park, Seong-Cheol ;

Kim, Mi-Hyun ;

Hossain, Mohammed Akhter ;

Shin, Song Yub ;

Kim, Yangmee ;

Stella, Lorenzo ;

Wade, John D. ;

Park, Yoonkyung ;

Hahm, Kyung-Soo .

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2008, 1778 (01) :229-241

[24] Cytotoxicity and apoptosis mediated by two peptides of innate immunity [J].

Risso, A ;

Zanetti, M ;

Gennaro, R .

CELLULAR IMMUNOLOGY, 1998, 189 (02) :107-115

[25] PPARγ:: a nuclear regulator of metabolism, differentiation, and cell growth [J].

Rosen, ED ;

Spiegelman, BM .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (41) :37731-37734

[26] Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers [J].

Steck, PA ;

Pershouse, MA ;

Jasser, SA ;

Yung, WKA ;

Lin, H ;

Ligon, AH ;

Langford, LA ;

Baumgard, ML ;

Hattier, T ;

Davis, T ;

Frye, C ;

Hu, R ;

Swedlund, B ;

Teng, DHF ;

Tavtigian, SV .

NATURE GENETICS, 1997, 15 (04) :356-362

[27] Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells [J].

Suttmann H. ;

Retz M. ;

Paulsen F. ;

Harder J. ;

Zwergel U. ;

Kamradt J. ;

Wullich B. ;

Unteregger G. ;

Stöckle M. ;

Lehmann J. .

BMC Urology, 8 (1)

[28] Binding analysis of glycyrrhetinic acid to human serum albumin: Fluorescence spectroscopy, FTIR, and molecular modeling [J].

Tang, JH ;

Luan, F ;

Chen, XG .

BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (09) :3210-3217

[29] Fat and beyond:: The diverse biology of PPARγ [J].

Tontonoz, Peter ;

Spiegelman, Bruce M. .

ANNUAL REVIEW OF BIOCHEMISTRY, 2008, 77 :289-312

[30] Inhibition of nuclear factor-κB activation by 2′,8"-biapigenin [J].

Woo, Eun-Rhan ;

Pokharel, Yuba Raj ;

Yang, Jin Won ;

Lee, Song Yi ;

Kang, Keon Wook .

BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (05) :976-980

← 1 2 3 4 →